IRIS
BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.683
EU - Europa 602
AS - Asia 231
AF - Africa 29
OC - Oceania 1
Totale 2.546
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.681
IE - Irlanda 268
SE - Svezia 161
SG - Singapore 144
IT - Italia 97
CN - Cina 71
GB - Regno Unito 56
CI - Costa d'Avorio 26
IN - India 11
FI - Finlandia 5
AT - Austria 4
DE - Germania 4
BE - Belgio 2
CA - Canada 2
NG - Nigeria 2
RU - Federazione Russa 2
UA - Ucraina 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
FR - Francia 1
JP - Giappone 1
MA - Marocco 1
MY - Malesia 1
Totale 2.546
Salva come PNG Salva come JPEG
Città #
Chandler 297
Dublin 268
Ashburn 226
Boardman 157
Fairfield 123
Lawrence 104
Princeton 104
San Diego 59
Washington 52
Des Moines 49
New York 48
Dallas 42
Seattle 28
Abidjan 26
London 26
Turin 24
Redmond 21
Singapore 21
Pune 11
Cambridge 9
Woodbridge 9
Ancona 8
Guangzhou 8
Houston 8
Shanghai 7
Los Angeles 6
Marche 5
Bologna 4
Boydton 4
Clifton 4
Helsinki 4
Hounslow 4
Macerata 4
Southwark 4
Vienna 4
Chiswick 3
Islington 3
Kilburn 3
Prescot 3
Rome 3
Wandsworth 3
Ann Arbor 2
Beijing 2
Brussels 2
Dueville 2
Genoa 2
Hanoi 2
Ikeja 2
Jiaxing 2
Jinhua 2
Mountain View 2
New Bedfont 2
Sassari 2
Tolentino 2
Toronto 2
Wilmington 2
Wuhan 2
Wuxi 2
Campobasso 1
Centro 1
Changsha 1
Chicago 1
Falconara Marittima 1
Falkenstein 1
Falls Church 1
Forest City 1
Gatchina 1
Hangzhou 1
Laurel 1
Miami Beach 1
Mondolfo 1
Nashville 1
Nuremberg 1
Palermo 1
Pedaso 1
Petaling Jaya 1
Ravenna 1
San Francisco 1
Santa Clara 1
Shenzhen 1
Suzuka 1
Tiantai Chengguanzhen 1
Totale 1.854
Salva come PNG Salva come JPEG
Nome #
The application of cancer stem cell model in malignant mesothelioma 72
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 56
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 54
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 48
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 46
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 46
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 42
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 40
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 40
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 37
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 36
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 35
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 35
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 35
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 34
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 34
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 33
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 33
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 33
New generation anaplastic lymphoma kinase inhibitors 32
Germline copy number variation in the YTHDC2 gene: Does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 32
Sorafenib for the treatment of breast cancer 32
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 31
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 31
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 31
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 31
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 30
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 30
Bortezomib: A new pro-apoptotic agent in cancer treatment 30
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 30
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 30
How much of familial breast cancer risk is currently explained by the known genes? 30
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 29
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 29
The role of targeted therapy for gastrointestinal tumors 29
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 29
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 29
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 28
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 28
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 28
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 28
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 27
Cancer and the microbiome: Potential applications as new tumor biomarker 27
VIPoma and PPoma 27
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 27
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 26
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 26
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 26
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 26
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 25
EGFR genomic alterations in cancer: prognostic and predictive values 25
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 25
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 25
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 24
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 24
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 24
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 24
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 24
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 24
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 23
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 23
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 22
A headlight on liquid biopsies: a challenging tool for breast cancer management 22
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 22
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 21
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 21
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 21
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 19
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 19
Anti-endothelin drugs in solid tumors 19
MicroRNAs in colorectal cancer stem cells: New regulators of cancer stemness? 19
Nintedanib in NSCLC: Evidence to date and place in therapy 18
Fully human antibodies for malignant pleural mesothelioma targeting 18
Colorectal cancer 18
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 17
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 17
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 17
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 17
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 16
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 16
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 16
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 16
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 16
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 15
Dietary restriction: could it be considered as speed bump on tumor progression road? 15
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 15
Targeted therapies in hepatocellular carcinoma 15
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 14
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 14
HER2-positive male breast cancer: An update 14
Multisciplinary management of patients with liver metastasis from colorectal cancer 14
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 14
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 14
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 13
Tmb in nsclc: A broken dream? 13
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 13
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 13
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 13
Sex steroids, carcinogenesis, and cancer progression 13
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 13
Totale 2.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.838
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.838
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 0 0 0 0 0 0 0 237 13 153 112
2022/20231.116 106 67 91 59 78 196 2 55 343 5 81 33
2023/2024846 157 17 79 122 158 185 18 27 0 9 20 54
2024/2025264 91 173 0 0 0 0 0 0 0 0 0 0
Totale 2.741